NCT03287609 - EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) | Biotech Hunter

Enrollment

308

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

May 20, 2019

Study Completion Date

August 7, 2019

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Evolocumab 140 mg/mL

Three injections with pre-filled auto-injector pen at day 1 and at week 4.

DRUG

Placebo

Three injections with pre-filled auto-injector pen at day 1 and at week 4.

Trial Locations (7)

Hopitaux Universitaires Geneve, Geneva

HFR Kantonsspital, Fribourg

Bern University Hospital, Bern

Basel University Hospital, Basel

Cardiocentro Ticino, Lugano

Centre Hospitalier Universitaire Vaudois, Lausanne

University Hospital, Zurich